Financial Daily from THE HINDU group of publications
Saturday, Jun 14, 2003
Financial Daily from THE HINDU group of publications Saturday, Jun 14, 2003 |
|
|
|
|
|
Corporate
-
Announcements Dr Reddy's to present research findings at US meet Our Bureau
HYDERABAD, June 13 DR Reddy's Laboratories Ltd, the Hyderabad-based drug major listed on the New York Stock Exchange (NYSE), has announced that it would be presenting six abstracts, representing its discovery research findings, at the 63rd Scientific Sessions of the American Diabetes Association being held from June 13 to 17 at New Orleans, US. In a press release, the company said the abstracts being presented would feature the progress of Dr Reddy's discovery programme, which would include demonstration of preclinical efficacy and safety of the company's pipeline compounds in development for treatment of type-2 diabetes, discovery of potential new diagnostic markers for onset of type-2 diabetes and mechanisms of accelerated cardiovascular disease in diabetics. The American Diabetes Association (ADA) is a leading non-profit health organisation based in the US and provides diabetes research, information and advocacy. More than 8,000 attendees were expected to participate in these sessions, including physicians, scientists and other healthcare professionals involved in diabetes research and care. This is the third successive year that Dr Reddy's scientists were presenting their research findings at the ADA. The annual ADA meetings were the premier platform for presentation of diabetes related research. The abstracts were peer-reviewed before being accepted for presentation, the company said. Further, the company has also announced that it would hold its Scientific Advisory Board meeting in New Orleans on June 14. The Board, consisting of international scientific opinion leaders, would review the progress in the company's discovery research programme in the areas of diabetes, cardiovascular disease and inflammation. A clinical consortium meeting in Atlanta on June 18 would follow this board meeting. The consortium would consist of a panel of international experts who would review the progress of and strategy for the clinical development of the company's anti-cancer molecules, the release said.
Article E-Mail :: Comment :: Syndication
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |
Copyright © 2003, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|